Spero Therapeutics, Inc.
SPRO
Rank in Stocks
#21810
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical... Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$1.07
Last synced: 2026-11-09
Market Cap
$62.31M
Change (1 day)
3.88%
Change (1 year)
-59.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Spero Therapeutics, Inc. (SPRO)
Category
Healthcare
Dividend history for Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (stock symbol: SPRO) made a total of 23 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $0.29
Dividend yield (TTM) : 0.00%
The sum of all dividends (adjusted for stock splits) is : $0.29
Dividend yield (TTM) : 0.00%
Dividend payments for Spero Therapeutics, Inc. (SPRO) from 2010 to 2026
Annual dividend payments
| Year | Dividend (stock split adjusted) | Change |
|---|---|---|
| 2026 (TTM) | $0.06 | 33.33% |
| 2015 | $0.045 | -25.00% |
| 2014 | $0.06 | 0.00% |
| 2013 | $0.06 | 50.00% |
| 2012 | $0.04 | 0.00% |
| 2011 | $0.04 | 0.00% |
| 2010 | $0.04 | 0.00% |
List of all dividend payments
| Year | Dividend | Change |
|---|---|---|
| 2026 (TTM) | $0.06 | 33.33% |
| 2015 | $0.045 | -25.00% |
| 2014 | $0.06 | 0.00% |
| 2013 | $0.06 | 50.00% |
| 2012 | $0.04 | 0.00% |
| 2011 | $0.04 | 0.00% |
| 2010 | $0.04 | 0.00% |
Dividend payments for similar companies or competitors
| Company | Number of dividend payments | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 67.00% |
AU
|
|
| 30.00% |
BE
|
|
| 0.00% |
NL
|
Questions about Spero Therapeutics, Inc.'s dividend per share
What is Spero Therapeutics, Inc.'s dividend per share?
Spero Therapeutics, Inc.'s dividend per share over the last twelve months is $0.06, as of Sep 2015.
What was Spero Therapeutics, Inc.'s dividend per share in 2015?
In 2015, Spero Therapeutics, Inc.'s dividend per share was $0.05, 25.00% less than in 2014 ($0.06).
How has Spero Therapeutics, Inc.'s dividend per share changed since 2010?
From 2010 to 2015, Spero Therapeutics, Inc.'s dividend per share went from $0.04 to $0.05, an average growth of 2.38% a year.